<DOC>
	<DOC>NCT00810940</DOC>
	<brief_summary>This is a randomized, controlled clinical trial at three sites to determine the safety and preliminary efficacy of the study drug to treat severe head trauma (GCS 4-8). It is hypothesized that the drug may lower pressure in the brain, reduce mortality and the patient may have improved neurological function following treatment.</brief_summary>
	<brief_title>Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury</brief_title>
	<detailed_description />
	<mesh_term>Craniocerebral Trauma</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Diagnosis TBI GCS 48 Age 1670 Multiple trauma resulting in shock Bilateral absent pupil response Time from injury &gt; 6 hours Brain tumor or mass effect secondary to hemorrhage or brain surgery Pregnancy Confounding condition or injury Spinal cord injury Sustained high blood pressure or arterial oxygen saturation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>TBI</keyword>
	<keyword>closed head injury</keyword>
	<keyword>severe head trauma</keyword>
	<keyword>traumatic brain injury</keyword>
</DOC>